SCHEMBL11973759

SCHEMBL11973759

O=[N+]([O-])c1cc(F)c(Cl)cc1S(=O)(=O)Nc1ccc(Cl)c2cccnc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 15/20 0.66
▸ ALDH1A1 P00352 2/20 0.53
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ TDP1 Q9NUW8 4/20 0.52
▸ NFKBIA P25963 3/20 0.52
▸ RELA Q04206 3/20 0.52
▸ OPRK1 P41145 2/20 0.52
▸ MDM4 O15151 1/20 0.52
▸ MDM2 Q00987 1/20 0.52
▸ AGTR1 P30556 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ PKM P14618 2/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11972986 0.95 SLC40A1 (0.67) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11973728 0.87 SLC40A1 (0.68) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11973230 0.84 SLC40A1 (0.62) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11972945 0.84 SLC40A1 (0.71) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11972890 0.84 SLC40A1 (0.72) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11973415 0.84 SLC40A1 (0.70) SLC40A1MEN1KMT2ATDP1NFKBIA
SCHEMBL11973633 0.79 SLC40A1 (0.69) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11973317 0.79 SLC40A1 (1.00) SLC40A1KDM4E
SCHEMBL11972815 0.78 SLC40A1 (0.68) SLC40A1ALDH1A1MEN1KMT2ATDP1
SCHEMBL11973886 0.78 SLC40A1 (0.71) SLC40A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 — — EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 — — US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 — — US disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 — — EP disclosed
WO-2012110603-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — WO disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885ALDH1A1 3570/4885MEN1 2680/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 SLC40A1 2/4885ALDH1A1 3570/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback